Press release
Post-Polycythemia Vera Myelofibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight | Kartos Therapeutics, Inc., Parexel, Constellation Pharmaceuticals, Incyte
Post-Polycythemia Vera Myelofibrosis Clinical Trials
According to DelveInsight, the Post-Polycythemia Vera Myelofibrosis pipeline comprises 17+ pharmaceutical and biotech companies actively developing 17+ therapeutic candidates targeting Post-Polycythemia Vera Myelofibrosis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
With Post-Polycythemia Vera Myelofibrosis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options.
Explore the Cutting-Edge Landscape of Post-Polycythemia Vera Myelofibrosis Drug Development @ https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Post-Polycythemia Vera Myelofibrosis Pipeline Report
• DelveInsight's Post-Polycythemia Vera Myelofibrosis pipeline report depicts a robust space with 17+ active players working to develop 17+ pipeline therapies for Post-Polycythemia Vera Myelofibrosis treatment.
• In July 2025, Celgene has announced a Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
• In July 2025, Incyte Corporation has announced results of a Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
• In June 2025, Swedish Orphan Biovitrum has announced results of a Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia.
• In September 2023, the FDA approved momelotinib for the treatment of adults with intermediate- or high-risk myelofibrosis, including PPV-MF, who have anemia. Momelotinib is a once-daily oral inhibitor of JAK1, JAK2, and activin A receptor type 1 (ACVR1). It is the first therapy approved that addresses anemia, constitutional symptoms, and splenomegaly in myelofibrosis patients.
• Key Post-Polycythemia Vera Myelofibrosis companies such as Kartos Therapeutics, Inc., Parexel, Constellation Pharmaceuticals, Incyte Corporation, NS Pharma, Celgene, Lynk Pharmaceuticals Co., Ltd, Imago BioSciences, Inc., Karyopharm Therapeutics Inc, and others are evaluating new drugs for Post-Polycythemia Vera Myelofibrosis to improve the treatment landscape.
• Promising Post-Polycythemia Vera Myelofibrosis pipeline therapies in various stages of development include Navtemadlin, Selinexor, and others.
Post-Polycythemia Vera Myelofibrosis Overview:
When Polycythemia Vera progresses into myelofibrosis, it is known as post-polycythemia vera myelofibrosis (PPV-MF). Myelofibrosis (MF) is a rare, chronic form of blood cancer characterized by a malfunction in the bone marrow that leads to abnormal blood cell production and the development of fibrous scar tissue.
Interestingly, PPV-MF is now recognized as one of the most frequently diagnosed types of intracranial tumors in the United States, with an estimated 98,000 to 170,000 new cases reported annually. Several factors have contributed to this rising incidence. Advances in systemic therapies-especially immunotherapies-have extended the survival of patients with widespread metastatic disease, giving more time for secondary complications like PPV-MF to develop. Additionally, improvements in magnetic resonance imaging (MRI) technology have enhanced the ability to detect small, asymptomatic cases, contributing to more frequent diagnoses.
Download the Post-Polycythemia Vera Myelofibrosis sample report to know in detail about the Post-Polycythemia Vera Myelofibrosis treatment market @ https://www.delveinsight.com/sample-request/post-polycythemia-vera-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Post-Polycythemia Vera Myelofibrosis Pipeline Analysis
The Post-Polycythemia Vera Myelofibrosis pipeline insights report 2025, provides insights into:
• Provides comprehensive insights into key companies developing therapies in the Post-Polycythemia Vera Myelofibrosis Market.
• Categorizes Post-Polycythemia Vera Myelofibrosis therapeutic companies by development stage: early, mid, and late-stage.
• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Post-Polycythemia Vera Myelofibrosis drugs under development based on:
• Stage of development
• Post-Polycythemia Vera Myelofibrosis Route of administration
• Target receptor
• Monotherapy vs. combination therapy
• Post-Polycythemia Vera Myelofibrosis Mechanism of action
• Molecular type
Offers detailed analysis of:
• Company-to-company and company-academia collaborations
• Post-Polycythemia Vera Myelofibrosis Licensing agreements
• Funding and investment activities supporting future Post-Polycythemia Vera Myelofibrosis market advancement.
Unlock key insights into emerging Post-Polycythemia Vera Myelofibrosis therapies and market strategies here: https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Post-Polycythemia Vera Myelofibrosis Emerging Drugs
Navtemadlin - Kartos Therapeutics, Inc.
Navtemadlin (KRT-232) is an investigational cancer therapy that specifically targets and inhibits the MDM2 protein. Preclinical studies, including cell cultures and cancer models, have shown that navtemadlin effectively blocks MDM2 at low concentrations, triggering a dose-dependent activation of the p53 pathway. This activation leads to cell cycle arrest via p21 and promotes cell death through pro-apoptotic Bcl-2 family proteins, resulting in complete and sustained tumor regression. Promising clinical responses have been observed in patients with various advanced cancers such as myelofibrosis, acute myeloid leukemia, and Merkel cell carcinoma. The therapy is currently in Phase II/III trials for treating Post-Polycythemia Vera Myelofibrosis (Post-PV-MF).
Selinexor - Karyopharm Therapeutics Inc.
Selinexor is an innovative, orally administered drug that belongs to a class called Selective Inhibitors of Nuclear Export (SINE). It works by binding to and blocking the function of XPO1, a nuclear export protein. This inhibition causes tumor suppressor proteins to accumulate in the cell nucleus, restoring and enhancing their ability to suppress tumor growth. The process selectively triggers cancer cell death while sparing most normal cells. Selinexor is currently being evaluated in a Phase II clinical trial to assess its safety and effectiveness in patients with myelofibrosis-including primary (PMF), post-essential thrombocythemia (PET-MF), and post-polycythemia vera (PPV-MF) types-who are resistant or intolerant to JAK1/2 inhibitors.
Post-Polycythemia Vera Myelofibrosis Pipeline Therapeutic Assessment
Post-Polycythemia Vera Myelofibrosis Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Post-Polycythemia Vera Myelofibrosis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Post-Polycythemia Vera Myelofibrosis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Post-Polycythemia Vera Myelofibrosis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Post-Polycythemia Vera Myelofibrosis therapies and key Post-Polycythemia Vera Myelofibrosis companies: https://www.delveinsight.com/sample-request/post-polycythemia-vera-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Post-Polycythemia Vera Myelofibrosis Current Treatment Patterns
4. Post-Polycythemia Vera Myelofibrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Post-Polycythemia Vera Myelofibrosis Late-Stage Products (Phase-III)
7. Post-Polycythemia Vera Myelofibrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Post-Polycythemia Vera Myelofibrosis Discontinued Products
13. Post-Polycythemia Vera Myelofibrosis Product Profiles
14. Post-Polycythemia Vera Myelofibrosis Key Companies
15. Post-Polycythemia Vera Myelofibrosis Key Products
16. Dormant and Discontinued Products
17. Post-Polycythemia Vera Myelofibrosis Unmet Needs
18. Post-Polycythemia Vera Myelofibrosis Future Perspectives
19. Post-Polycythemia Vera Myelofibrosis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Post-Polycythemia Vera Myelofibrosis pipeline reports offerings: https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Post-Polycythemia Vera Myelofibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight | Kartos Therapeutics, Inc., Parexel, Constellation Pharmaceuticals, Incyte here
News-ID: 4136154 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Myelofibrosis
Primary Myelofibrosis (PMF) Market Insights and Future Outlook
Introduction
Primary myelofibrosis (PMF) is a rare, chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, splenomegaly, anemia, and systemic symptoms such as fatigue, night sweats, and weight loss. Unlike secondary myelofibrosis, which arises from other blood cancers, PMF develops as a distinct disease entity, typically driven by mutations in JAK2, CALR, or MPL genes.
PMF has long been associated with poor prognosis and limited therapeutic options. Historically, treatment focused on symptom…
Myelofibrosis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Myelofibrosis Pipeline Insight 2024" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Myelofibrosis Research. Learn more about our innovative…
Secondary Myelofibrosis Therapeutics Market - Revolutionizing Treatment for Seco …
Newark, New Castle, USA: The "Secondary Myelofibrosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Secondary Myelofibrosis Therapeutics Market: https://www.growthplusreports.com/report/secondary-myelofibrosis-therapeutics-market/8885
This latest report researches the industry structure,…
Myelofibrosis Market - Transforming Challenges into Triumphs: Myelofibrosis Mark …
Newark, New Castle, USA: The "Myelofibrosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Myelofibrosis Market: https://www.growthplusreports.com/report/myelofibrosis-market/8802
This latest report researches the industry structure, sales, revenue, price and…
Secondary Myelofibrosis Therapeutics Market - Unleashing Resilience, Defying Mye …
Newark, New Castle, USA - new report, titled Secondary Myelofibrosis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Secondary Myelofibrosis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Secondary Myelofibrosis Therapeutics market. The report offers an overview of…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
